Publications by authors named "Lynda C Schneider"

Article Synopsis
  • * Mild-to-moderate AD is typically treated with topical anti-inflammatory medications and basic skin care, while moderate-to-severe cases often need systemic therapy, including off-label immunosuppressants, which carry safety concerns.
  • * New targeted biologics and small molecules are emerging as more effective and safer treatment options for AD, leading to the development of standardized recommendations for treating pediatric patients with moderate-to-severe cases.
View Article and Find Full Text PDF
Article Synopsis
  • Moderate-to-severe atopic dermatitis (AD) significantly affects the quality of life for young children and their caregivers, with skin pain being a major symptom.
  • In a study involving 162 children aged 6 months to 5 years, those treated with dupilumab showed a greater reduction in skin pain compared to the placebo group after 16 weeks.
  • The results indicate that dupilumab treatment leads to rapid and significant improvements in skin pain, benefiting both the overall patient population and specific subgroups struggling with more severe symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • * The American Academy of Allergy, Asthma & Immunology has released updated guidelines for treating atopic dermatitis, focusing on trustworthy development standards and evidence-based medicine to guide clinical decisions.
  • * The guidelines include recommendations for various treatments like topical therapies, dietary changes, and systemic treatments, emphasizing the importance of considering patient values and preferences in treatment selection.
View Article and Find Full Text PDF
Article Synopsis
  • * Results reveal that children with food allergies have a higher likelihood of experiencing family food insecurity, particularly in families with lower income.
  • * The research suggests that access to allergen-free foods in assistance programs should be improved to help families facing food insecurity.
View Article and Find Full Text PDF
Article Synopsis
  • Dupilumab is a biologic medication approved for treating atopic dermatitis in kids aged 6 months to 17 years, and the study focused on its effects on associated health issues in these patients.* -
  • Using electronic health records, researchers matched 3,575 pediatric patients receiving dupilumab with the same number receiving other treatments, assessing the emergence of new health problems.* -
  • Results showed that dupilumab significantly reduced the risk of various comorbidities like asthma, infections, and psychiatric disorders, especially in younger children (0-5 years).*
View Article and Find Full Text PDF
Article Synopsis
  • Sunflower seeds are increasingly recognized as a common allergen-free alternative to peanuts, but they can also cause allergies.
  • A study conducted over 26 years identified 235 pediatric patients with sunflower seed allergy, primarily diagnosed at around 3.9 years old, and most had other related allergy conditions.
  • The study found that the incidence of sunflower seed allergies rose over time, with an annual increase of 21%, and reactions often ranged from mild skin issues to severe anaphylactic responses.
View Article and Find Full Text PDF

Background: Systemic Janus kinase inhibitors (JAKi) and dupilumab both have emerged as promising therapeutics for atopic dermatitis (AD). Dupilumab has a favorable safety profile, but oral JAKi therapy has been established in other diseases that carry potential comorbid susceptibilities that influence safety.

Objective: We sought to provide real-world evidence of the comparative safety of oral JAKi versus dupilumab in patients with AD.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by severe itching and skin lesions, commonly beginning in infancy and often linked to a family history of atopic diseases.
  • Environmental factors and T-helper type 2 cytokines play roles in triggering and worsening AD by damaging the skin barrier, which can lead to food allergies, particularly in children with the condition.
  • While elimination diets may provide temporary relief from food allergy symptoms in those with AD, they do not cure the condition and can lead to additional health issues, including allergies, nutritional deficiencies, and decreased quality of life.
View Article and Find Full Text PDF

Atopic dermatitis (AD) is associated with high levels of psychosocial burden, often resulting in poor mental health outcomes. Despite this association, few studies have evaluated the efficacy of mental health interventions within this population. Utilization of multidisciplinary and peer-led support, in addition to equipping patients with psychological tools, may be beneficial in improving mental health outcomes.

View Article and Find Full Text PDF

Global warming has direct and indirect effects, as well as short- and long-term impacts on the respiratory and skin barriers. Extreme temperature directly affects the airway epithelial barrier by disrupting the structural proteins and by triggering airway inflammation and hyperreactivity. It enhances tidal volume and respiratory rate by affecting the thermoregulatory system, causing specific airway resistance and reflex bronchoconstriction via activation of bronchopulmonary vagal C fibers and upregulation of transient receptor potential vanilloid (TRPV) 1 and TRPV4.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a skin condition that causes inflammation and can be treated in different ways, but it's not always clear which treatments work best.
  • Researchers looked at many studies to compare the benefits and risks of different treatments for AD.
  • They found that some treatments, like high-dose upadacitinib, were very effective but also had more side effects, while others like dupilumab were safer but less powerful.
View Article and Find Full Text PDF

Introduction: Patients with atopic dermatitis (AD) are uniquely susceptible to a number of serious viral skin complications, including eczema herpeticum (EH), caused by herpes simplex virus. This study explored the associations between biomarkers of epithelial barrier dysfunction, type 2 immunity, Staphylococcus aureus infection, and S. aureus-specific immunoglobulin responses in a cohort of AD subjects with and without a history of EH (EH+ and EH-, respectively).

View Article and Find Full Text PDF

Background: Debates on the allocation of medical resources during the coronavirus disease 2019 (COVID-19) pandemic revealed the need for a better understanding of immunological risk. Studies highlighted variable clinical outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in individuals with defects in both adaptive and innate immunity, suggesting additional contributions from other factors. Notably, none of these studies controlled for variables linked with social determinants of health.

View Article and Find Full Text PDF

Background: Debates on the allocation of medical resources during the COVID-19 pandemic revealed the need for a better understanding of immunologic risk. Studies highlighted variable clinical outcomes of SARS-CoV-2 infections in individuals with defects in both adaptive and innate immunity, suggesting additional contributions from other factors. Notably, none of these studies controlled for variables linked with social determinants of health.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored atopic dermatitis (AD), a chronic skin condition, to link its severity with historical and clinical features as well as biomarkers.
  • A total of 2,862 participants were categorized into mild, moderate, and severe AD, with findings showing that severity is associated with several factors including a personal/family history of allergic disorders and certain skin conditions.
  • Key indicators of severity included high serum IgE levels, eosinophilia, and specific skin manifestations, along with a range of bacterial and viral skin infections, highlighting the complex nature of AD.
View Article and Find Full Text PDF
Article Synopsis
  • The study aims to synthesize patient and caregiver values and preferences in managing atopic dermatitis (AD) to aid the development of clinical guidelines by relevant allergy associations.* ! -
  • A thorough review of numerous studies revealed that participants generally favor starting with nonmedical treatments and are concerned about side effects from medications, highlighting the importance of a strong patient-clinician relationship.* ! -
  • Findings indicate that patients prefer treatments that are odorless, minimally visible, and have a low impact on daily activities, with a specific emphasis on relieving itching and burning sensations.* !
View Article and Find Full Text PDF

Background: Current systemic treatments for children younger than 6 years with moderate-to-severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal efficacy and safety. Dupilumab is approved for older children and adults with atopic dermatitis and for other type 2 inflammatory conditions. We aimed to evaluate efficacy and safety of dupilumab with concomitant low-potency topical corticosteroids in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis.

View Article and Find Full Text PDF

Background: Emergency department visits for anaphylaxis have increased considerably over the past few decades, especially among children. Despite this, anaphylaxis management remains highly variable and contributes to significant health care spending. On the basis of emerging evidence, in this quality improvement project we aimed to safely decrease hospitalization rates, increase the use of cetirizine, and decrease use of corticosteroids for children with anaphylaxis by December 31, 2019.

View Article and Find Full Text PDF

Background: Treatment options for peanut allergy are limited. In previous clinical trials, epicutaneous immunotherapy with a patch containing 250-μg peanut protein (Viaskin Peanut 250 μg [VP250]) was well tolerated and statistically superior to placebo in desensitizing peanut-allergic children.

Objective: To examine the safety of VP250 in children, using a study design approximating potential real-world use.

View Article and Find Full Text PDF

Background: Total serum IgE (tIgE) is an important intermediate phenotype of allergic disease. Whole genome genetic association studies across ancestries may identify important determinants of IgE.

Objective: We aimed to increase understanding of genetic variants affecting tIgE production across the ancestry and allergic disease spectrum by leveraging data from the National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine program; the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA); and the Atopic Dermatitis Research Network (N = 21,901).

View Article and Find Full Text PDF
Article Synopsis
  • Scientists want to figure out what we don’t know about anaphylaxis, which is a severe allergy reaction, so they can use their resources better.
  • A group of 25 experts created a list of important questions and topics that need more research about anaphylaxis, like diagnosis and treatment.
  • They came up with 98 statements to prioritize which ones are the most important to study and found that improving diagnosis and treatment methods is very important.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers examined how well polygenic risk scores (PRSs) can predict the occurrence and severity of atopic dermatitis (AD) by using genetic information.
  • They utilized a dataset of 1,619 European American individuals and included data from related allergic conditions and specific genetic mutations (FLG LOF variants).
  • Results showed that incorporating a broader range of genetic data significantly improved the prediction accuracy for AD and its severity, suggesting PRSs could be a valuable tool in identifying individuals at higher risk for severe AD.
View Article and Find Full Text PDF

Background: Laboratory testing is typically required for patients with atopic dermatitis (AD) treated with systemic immunosuppressants. A previous analysis of laboratory outcomes in randomized, double-blinded, placebo-controlled clinical trials of dupilumab in adults with moderate-to-severe AD found no clinically important changes in hematologic, serum chemistry, and urinalysis parameters, supporting the use of dupilumab without routine laboratory monitoring.

Objective: The aim was to assess laboratory results in adolescents with moderate-to-severe AD treated with dupilumab in a phase 3, randomized, double-blind, placebo-controlled trial.

View Article and Find Full Text PDF

Background: Eczema herpeticum (EH) is a rare complication of atopic dermatitis (AD) caused by disseminated herpes simplex virus (HSV) infection. The role of rare and/or deleterious genetic variants in disease etiology is largely unknown. This study aimed to identify genes that harbor damaging genetic variants associated with HSV infection in AD with a history of recurrent eczema herpeticum (ADEH+).

View Article and Find Full Text PDF